Haim Pharma Group

Company Overview

Snapshot

Founded in April 2022 by Miriam O’reilly, Haim Pharma Group operates with 1–10 employees. The company has raised $68,000 across two funding rounds from one investor. In September 2025, Haim Pharma Group secured a grant from the Israel Innovation Authority.

Business overview

Haim Pharma Group (HPG) is an Israel-based virtual drug development company focused on advancing stabilized synthetic psilocin as a first-in-class therapy for neurodegenerative diseases. The company's core product, Neurosilin, is an oral enteric-coated psilocin capsule designed for stability and controlled release, targeting conditions like amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). HPG leverages psilocin’s multimodal mechanisms, including serotonin receptor engagement and neuroplasticity enhancement, to slow disease progression. The company operates through a virtual model, coordinating with global CROs, CDMOs, and academic partners, serving the pharmaceutical and life sciences markets within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is Haim Pharma Group's primary therapeutic focus?

Haim Pharma Group is focused on developing stabilized synthetic psilocin formulations for neurodegenerative diseases, with a lead program targeting amyotrophic lateral sclerosis (ALS) and a parallel program for Parkinson’s disease (PD).

What is Neurosilin?

Neurosilin is Haim Pharma Group's pioneering oral enteric-coated psilocin capsule, designed for stability and controlled release, intended for chronic, sub-hallucinogenic dosing to treat neurodegenerative diseases.

When did Haim Pharma Group secure its most recent grant funding?

In September 2025, Haim Pharma Group secured a grant from the Israel Innovation Authority.

What regulatory steps has Haim Pharma Group taken?

Haim Pharma Group engaged with the FDA and submitted a briefing package in July 2025, outlining its development strategy and clinical roadmap for its psilocin-based therapies.

What is the total capital raised by Haim Pharma Group?

Haim Pharma Group has raised a total of $68,000 across two funding rounds.